^
    PD-L1 negative
    Melanoma
    pembrolizumab + ipilimumab
    Sensitive
    :
    C3
    J Clin Oncol - 1wk
    BRAF V600K + CDKN2A deletion + RB1 expression
    Melanoma
    vemurafenib + palbociclib
    Sensitive
    :
    C3
    Clin Cancer Res - 1wk
    BRAF V600E + CDKN2A deletion + RB1 expression
    Melanoma
    vemurafenib + palbociclib
    Sensitive
    :
    C3
    Clin Cancer Res - 1wk
    ARAF mutation + NRAS mutation
    Melanoma
    HM95573
    Resistant
    :
    D
    Nature - 1wk
    BRAF V600E
    Melanoma
    Immunotherapy
    Resistant
    :
    C3
    SID 2021 - 3wk
    BRAF V600
    Melanoma
    vemurafenib + atezolizumab + cobimetinib
    Sensitive
    :
    A1
    BRAF V600E
    Melanoma
    dabrafenib
    Sensitive
    :
    A1
    BRAF V600E
    Melanoma
    trametinib + dabrafenib
    Sensitive
    :
    A1
    BRAF V600
    Melanoma
    binimetinib + encorafenib
    Sensitive
    :
    A1
    BRAF V600K
    Melanoma
    trametinib + dabrafenib
    Sensitive
    :
    A1
    No biomarker
    Melanoma
    pembrolizumab
    Sensitive
    :
    A1
    BRAF V600E
    Melanoma
    vemurafenib + cobimetinib
    Sensitive
    :
    A1
    BRAF V600
    Melanoma
    vemurafenib + cobimetinib
    Sensitive
    :
    A1
    BRAF V600E
    Melanoma
    vemurafenib
    Sensitive
    :
    A1
    BRAF V600E
    Melanoma
    trametinib
    Sensitive
    :
    A1
    No biomarker
    Melanoma
    nivolumab
    Sensitive
    :
    A1
    No biomarker
    Melanoma
    ipilimumab
    Sensitive
    :
    A1
    No biomarker
    Melanoma
    nivolumab + ipilimumab
    Sensitive
    :
    A1
    PD-L1 underexpression
    Melanoma
    ipilimumab
    Sensitive
    :
    A1
    PD-L1 underexpression
    Melanoma
    nivolumab + ipilimumab
    Sensitive
    :
    A1
    BRAF V600
    Melanoma
    dabrafenib
    Sensitive
    :
    A1
    No biomarker
    Melanoma
    trametinib
    Resistant
    :
    A1
    BRAF V600
    Melanoma
    trametinib + dabrafenib
    Sensitive
    :
    A1
    BRAF V600
    Melanoma
    trametinib
    Sensitive
    :
    A1
    BRAF V600K
    Melanoma
    trametinib
    Sensitive
    :
    A1
    BRAF V600
    Melanoma
    vemurafenib
    Sensitive
    :
    A1
    No biomarker
    Cutaneous Melanoma
    ipilimumab
    Sensitive
    :
    A1
    BRAF V600K
    Melanoma
    binimetinib + encorafenib
    Sensitive
    :
    A1
    BRAF V600E
    Melanoma
    binimetinib + encorafenib
    Sensitive
    :
    A1
    VERI is free for non-commercial use, no login needed.
    Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
    For commercial access, including additional premium features, please contact us.
    By using VERI, you are agreeing to our
    and
    Privacy Policy
    ACCEPT COOKIES